Cook MyoSite Announces Plan for Employment Expansion

Cook MyoSite Announces Plan for Employment Expansion

<0> Cook MedicalCaitlin Wenz, 812-339-2235 ext. 4245Cell: 812-327-4433Specialist, Public Relations </0>

Cook MyoSite Incorporated is expanding its workforce to more than double its current size by 2015. By the end of 2012 alone, Cook MyoSite plans to hire 12-15 new employees.

Cook MyoSite is a part of the Cook Group Inc. family of companies. MyoSite is a biotechnology company that develops cellular therapies to treat disorders of the body naturally. The company was formed in 2002 and recently celebrated its 10 anniversary. With ties to the Pittsburgh life sciences community, Cook MyoSite works to support the Pittsburgh community and continue Cook Medical’s commitment to local economic development.

“We are very excited about the new technologies on the horizon for Cook MyoSite,” said Richard Faulk, director of business process management for Cook MyoSite. “We are looking forward to the expansion because it will help to accommodate our clinical and market goals as well as help to support the business economy here in Pittsburgh.”

MyoSite’s core technology involves isolating and regrowing adult muscle-derived cells from a patient’s muscle biopsy and then injecting those cells back into the patient’s body for a therapeutic effect. The company is currently conducting a phase III clinical trial in Canada and Europe for female stress urinary incontinence, as well as early-phase clinical trials in Canada for fecal incontinence and myocardial infarction.

As Cook MyoSite expands in size to promote further innovation, the company is looking for people to fill a variety of professional and scientific positions. If you would like more information or are interested in employment with Cook MyoSite, please contact Erin Feth, at:.

MyoSite is a Cook Medical biotechnology company in Pittsburgh, Pennsylvania. A global pioneer in breakthrough medical technologies, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. In 2002, Cook Medical formed Cook MyoSite to guide the company into the expanding world of cellular technologies. For more information on the company, visit or visit Follow Cook Medical on and

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.